Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603866 | 0.89 | MEN1 (0.45) | SMN1; SMN2MAPTTP53BCHEACHE | |
| SCHEMBL3603569 | 0.87 | MAPT (0.41) | SMN1; SMN2MAPTTP53BCHEACHE | |
| SCHEMBL3595020 | 0.84 | HSD17B10 (0.52) | SMN1; SMN2MAPTTP53GAATSHR | |
| SCHEMBL3595659 | 0.84 | MEN1 (0.41) | MAPTTP53GAATSHRTHRB | |
| SCHEMBL3591244 | 0.84 | TSHR (0.42) | SMN1; SMN2MAPTTP53BCHEACHE | |
| SCHEMBL13116000 | 0.84 | GRIN2B (0.43) | MAPTTP53BCHEACHEGAA | |
| SCHEMBL3598310 | 0.81 | NPC1 (0.46) | SMN1; SMN2MAPTTP53BCHETSHR | |
| SCHEMBL3601863 | 0.80 | GRIN2B (0.45) | MAPTTP53BCHEACHEGAA | |
| SCHEMBL3599800 | 0.78 | HPGD (0.47) | MAPTTP53BCHEACHEGAA | |
| SCHEMBL3600905 | 0.78 | GRIN2B (0.46) | MAPTTP53GAATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | SMN1; SMN2 4228/4885MAPT 2809/4885TP53 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.